Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression
- 1 January 2000
- book chapter
- Published by Elsevier
- Vol. 313, 268-284
- https://doi.org/10.1016/s0076-6879(00)13017-4
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding proteinNature Medicine, 1997
- Multiple Mechanisms May Contribute to the Cellular Anti-Adhesive Effects of Phosphorothioate OligodeoxynucleotidesNucleic Acids Research, 1996
- Does antisense exist?Nature Medicine, 1995
- Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular MatrixPublished by Elsevier ,1995
- Aptameric inhibition of p210bcr-abltyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structureNucleic Acids Research, 1994
- Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?Science, 1993
- Current concepts in antisense drug designJournal of Medicinal Chemistry, 1993
- Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cellsBiochemistry, 1993
- Phosphorothioate Oligodeoxynucleotides Bind to the Third Variable Loop Domain (v3) of Human Immunodeficiency Virus Type 1 gp120Antisense Research and Development, 1993
- Antisense oligonucleotides: a new therapeutic principleChemical Reviews, 1990